Samsung Biologics announced the completion of its purchase of a two‑cGMP biologics manufacturing plant in Rockville, Maryland, on March 31 2026. The $280 million deal adds a 60,000‑liter drug‑substance capacity facility to Samsung’s portfolio and marks the company’s first U.S. manufacturing site, bringing its global capacity to 845,000 liters.
The Rockville plant, which will continue to produce biologics for GSK under a supply‑chain agreement, will house more than 500 employees who transition to Samsung Biologics. The facility’s two‑cGMP designation and 60,000‑liter capacity position it to support a range of biologic products, and the continued partnership with GSK ensures a steady production pipeline for two key medicines on U.S. soil.
For Samsung Biologics, the acquisition is a strategic milestone that expands its geographic footprint and supports its three‑pillar growth strategy—capacity expansion, portfolio breadth, and global reach. Adding the Rockville site strengthens Samsung’s ability to serve North American clients, enhances operational flexibility, and positions the company to take on additional contract manufacturing projects in the U.S. market.
From GSK’s perspective, divesting the Rockville site aligns with its broader supply‑chain resilience strategy. The agreement guarantees the manufacture of two important medicines for U.S. patients and allows GSK to focus on its own network while maintaining a reliable U.S. production partner.
Industry analysts note that Samsung’s move reflects a broader trend of biopharmaceutical companies investing in U.S. manufacturing to mitigate supply‑chain risks and meet regulatory expectations. Samsung plans further investments to expand capacity and upgrade technologies at the Rockville site, reinforcing its commitment to a diversified global manufacturing network.
"This represents a meaningful step in expanding our U.S. manufacturing footprint. The addition of the Rockville team strengthens our ability to operate a geographically diversified manufacturing network, and we are thrilled to officially welcome more than 500 colleagues at the site to the Samsung Biologics family." – John Rim, President and CEO, Samsung Biologics
"The Rockville team brings deep expertise and strong operational experience that will further strengthen the site as part of our global manufacturing network. As a CDMO, our mission is to help our partners bring important therapies to patients worldwide, and this site will play a pivotal role in that mission while ensuring continuity and upholding the high standards our clients expect." – John Rim, President and CEO, Samsung Biologics
"Today's agreement to divest the Rockville manufacturing site to our valued long‑term partner, Samsung Biologics, will secure the manufacture of two important medicines on US soil for US patients and further build GSK's supply chain resilience." – Regis Simard, President, Global Supply Chain, GSK
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.